We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.09% | 75.73 | 75.72 | 75.80 | 2,283 | 10:02:02 |
From May 2019 to May 2024
By Adria Calatayud
AstraZeneca PLC said Monday that a Phase 3 trial to assess the potential of its Farxiga diabetes drug to treat patients with Covid-19 at risk of developing serious complications didn't achieve statistical significance for its primary target.
The trial didn't achieve statistical significance for the primary endpoint of prevention, measuring organ dysfunction and all-cause mortality, and of recovery, measuring a change in clinical status from early recovery to death, at 30 days, the British pharmaceutical giant said.
The full trial results will be presented at the American College of Cardiology Scientific Sessions in May, AstraZeneca said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
April 12, 2021 02:33 ET (06:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
